Literature DB >> 17609873

[Determination of organ doses and effective doses in radiooncology].

Jakob Roth1, Aurélien Emmanuel Martinez.   

Abstract

BACKGROUND AND
PURPOSE: With an increasing chance of success in radiooncology, it is necessary to estimate the risk from radiation scatter to areas outside the target volume. The cancer risk from a radiation treatment can be estimated from the organ doses, allowing a somewhat limited effective dose to be estimated and compared.
MATERIAL AND METHODS: The doses of the radiation-sensitive organs outside the target volume can be estimated with the aid of the PC program PERIDOSE developed by van der Giessen. The effective doses are determined according to the concept of ICRP, whereby the target volume and the associated organs related to it are not taken into consideration.
RESULTS: Organ doses outside the target volume are generally < 1% of the dose in the target volume. In some cases, however, they can be as high as 3%. The effective doses during radiotherapy are between 60 and 900 mSv, depending upon the specific target volume, the applied treatment technique, and the given dose in the ICRU point.
CONCLUSION: For the estimation of the radiation risk, organ doses in radiooncology can be calculated with the aid of the PC program PERIDOSE. While evaluating the radiation risk after ICRP, for the calculation of the effective dose, the advanced age of many patients has to be considered to prevent that, e.g., the high gonad doses do not overestimate the effective dose.

Entities:  

Mesh:

Year:  2007        PMID: 17609873     DOI: 10.1007/s00066-007-1697-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  6 in total

1.  Second malignancies in high‑dose areas of previous tumor radiotherapy.

Authors:  Birgitta Welte; Peter Suhr; Dirk Bottke; Detlef Bartkowiak; Wolfgang Dörr; Klaus Rüdiger Trott; Thomas Wiegel
Journal:  Strahlenther Onkol       Date:  2010-02-22       Impact factor: 3.621

2.  Exposure of treating physician to radiation during prostate brachytherapy using iodine-125 seeds: dose measurements on both hands with thermoluminescence dosimeters.

Authors:  Hans Schiefer; Friedrich von Toggenburg; Wolf Seelentag; Ludwig Plasswilm; Gerhard Ries; Cornelius Lenggenhager; Hans-Peter Schmid; Thomas Leippold; Ladislav Prikler; Bernd Krusche; Jakob Roth; Daniel Engeler
Journal:  Strahlenther Onkol       Date:  2009-10-06       Impact factor: 3.621

3.  Radiotherapy in early-stage Dupuytren's contracture. Long-term results after 13 years.

Authors:  Nicolas Betz; Oliver J Ott; Boris Adamietz; Rolf Sauer; Rainer Fietkau; Ludwig Keilholz
Journal:  Strahlenther Onkol       Date:  2010-01-28       Impact factor: 3.621

4.  Long-term outcome and prognostic factors in early-stage nodal low-grade non-hodgkin's lymphomas treated with radiation therapy.

Authors:  Hans Theodor Eich; Martina Heimann; Hartmut Stützer; Jan Kriz; Marcel Reiser; Rolf-Peter Müller
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

5.  Quasi-IMAT technique and secondary cancer risk in prostate cancer.

Authors:  Judith Alvarez Moret; Oliver Koelbl; Ludwig Bogner
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

6.  Wide tangential fields including the internal mammary lymph nodes in patients with left-sided breast cancer. Influence of respiratory-controlled radiotherapy (4D-CT) on cardiac exposure.

Authors:  Heidi Stranzl; Brigitte Zurl; Tanja Langsenlehner; Karin S Kapp
Journal:  Strahlenther Onkol       Date:  2009-03-28       Impact factor: 3.621

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.